V2X, INC (VVX) Announces Proposed 2.5M Share Secondary Offering

V2X, Inc. (NYSE: VVX) ("V2X" or the "company"), a leading provider of global mission solutions, announced today the commencement of an underwritten public offering of 2,500,000 shares of common stock by a certain selling stockholder. In connection with the offering, the selling stockholder intends to grant the underwriters an option to purchase up to 375,000 additional shares of common stock from the selling stockholder. V2X is not selling any shares of common stock in the offering, and V2X will not receive any proceeds from the offering by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Baird, Goldman Sachs & Co. LLC and Morgan Stanley are serving as lead joint book-running managers for the proposed offering.

A registration statement on Form S-3 (File No. 333-267223) relating to the shares of common stock of V2X to be sold in the proposed offering was declared effective by the Securities and Exchange Commission (the "SEC") on September 12, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering have been filed with the SEC and may be obtained by visiting EDGAR on the SEC's website at www.sec.gov or by contacting Baird, 777 East Wisconsin Avenue, Milwaukee, WI 53202, Attention: Syndicate Department, Telephone: 800-792-2473, Email: [email protected], Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282-2198, Attention: Prospectus Department, Telephone: 866-471-2526, Email: [email protected], or Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Manulife prices $750M subordinated notes offering at 6.146%
• Advent International offers $1.02 per share to acquire Definitive Healthcare
• Fortrea to buy Worldwide Clinical Trials' early phase unit for $45M